We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

Back to rankings

42 hedge funds and large institutions have $128M invested in Five Prime Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,800% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 1

1,827% more capital invested

Capital invested by funds: $6.62M → $128M (+$121M)

950% more funds holding

Funds holding: 4 → 42 (+38)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
42
Holders Change
+38
Holders Change %
+950%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
39
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HM
HealthCor Management
New York
+$14.9M
2
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
+$13.1M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$11.5M
4
WT
Wellcome Trust
United Kingdom
+$6.47M
5
Goldman Sachs
Goldman Sachs
New York
+$5.95M

Top Sellers

1
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
-$621K
2
MCM
Mazama Capital Management
Oregon
-$40K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.23K
Name Holding Trade Value Shares
Change 		Change in
Stake
WT
1
Wellcome Trust
United Kingdom
$22.5M +$6.47M +520,408 New
HM
2
HealthCor Management
New York
$20.1M +$14.9M +1,200,000 New
TGHSA
3
TPG Group Holdings (SBS) Advisors
Texas
$17.7M +$13.1M +1,053,692 New
Wellington Management Group
4
Wellington Management Group
Massachusetts
$15.5M +$11.5M +924,962 New
Goldman Sachs
5
Goldman Sachs
New York
$8.04M +$5.95M +478,966 New
BI
6
BVF Inc
California
$7.74M +$5.73M +461,000 New
Franklin Resources
7
Franklin Resources
California
$7.37M +$5.45M +438,700 New
AWMDMG
8
Austin W. Marxe & David M. Greenhouse
New York
$5.04M -$621K -50,000 -14%
PI
9
Putnam Investments
Massachusetts
$4.2M +$3.11M +250,000 New
BFA
10
BlackRock Fund Advisors
California
$2.51M +$1.86M +149,693 New
PA
11
Perceptive Advisors
New York
$2.23M +$1.65M +132,500 New
Alyeska Investment Group
12
Alyeska Investment Group
Illinois
$2.14M -$1.23K -99 -0.1%
BIT
13
BlackRock Institutional Trust
California
$1.47M +$1.09M +87,477 New
Northern Trust
14
Northern Trust
Illinois
$1.3M +$959K +77,167 New
ACPU
15
Arrowgrass Capital Partners (US)
Delaware
$1.26M +$932K +75,000 New
Allianz Asset Management
16
Allianz Asset Management
Germany
$1.01M +$745K +59,941 New
PAM
17
Panagora Asset Management
Massachusetts
$908K +$672K +54,079 New
Deutsche Bank
18
Deutsche Bank
Germany
$880K +$652K +52,498 New
Wells Fargo
19
Wells Fargo
California
$760K +$562K +45,257 New
State Street
20
State Street
Massachusetts
$704K +$521K +41,912 New
Vanguard Group
21
Vanguard Group
Pennsylvania
$665K +$492K +39,598 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$496K +$367K +29,572 New
WSA
23
Wall Street Associates
California
$420K – – –
CAM
24
Cormorant Asset Management
Massachusetts
$336K +$249K +20,000 New
GPCM
25
Granite Point Capital Management
Massachusetts
$336K +$249K +20,000 New
1
2

FPRX Hedge Fund Activity: Q4 2013 in Review

42 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2013, worth a combined $128M — up 1,827% from $6.62M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new FPRX positions and 1 closed out — a net gain of 38 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $14.9M. The largest seller was Austin W. Marxe & David M. Greenhouse, cutting an estimated $621K.

  • 42 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2013, up from 4 in Q3 2013.
  • Funds reported $128M of Five Prime Therapeutics, Inc. stock for Q4 2013, up 1,827% quarter-over-quarter.
  • 39 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2013 and 1 closed out, a net change of +38 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q4 2013 was HealthCor Management, an estimated $14.9M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q4 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $621K sold.

Based on aggregated 13F filings for Q4 2013.